Table 1.
Baseline Characteristics
| Treatment Group | Linezolid (n = 9) | Tedizolid (n = 15) | P Value |
|---|---|---|---|
| Age, median (IQR), y | 66 (61–72) | 64 (49–71) | .34 |
| Male, No. (%) | 8 (89) | 9 (60) | .19 |
| Race, No. (%) | .35 | ||
| White | 8 (89) | 10 (67) | - |
| Other | 1 (11) | 5 (33) | - |
| BMI, median (IQR), kg/m2 | 23 (22–26) | 27 (25–30) | .04 |
| Lung transplant, No. (%) | 9 (100) | 14 (93) | >.99 |
| Days since transplant, median (IQR) | 361 (162–669) | 200 (88–412) | .28 |
| Comorbidities, No. (%) | |||
| Cancer | 1 (11) | 1 (7) | >.99 |
| CHF | 1 (11) | 0 | .37 |
| COPD | 4 (44) | 1 (7) | .05 |
| CrCl,a median (IQR), mL/min | 67 (49–83) | 63 (56–97) | .90 |
| Cystic fibrosis | 0 | 2 (13.3) | .51 |
| Diabetes | 3 (33) | 12 (80) | .04 |
| ESRD | 1 (11) | 1 (7) | >.99 |
| Hypertension | 6 (67) | 11 (73) | >.99 |
| Liver disease | 0 (0) | 1 (7) | >.99 |
| Stroke | 0 (0) | 1 (7) | >.99 |
| Site of infection, No. (%) | - | ||
| Bacteremia | 1 (11) | 4 (27) | - |
| Disseminatedb | 1 (11) | 4 (27) | - |
| Osteomyelitis | 0 | 2 (13) | - |
| Pulmonary | 7 (78) | 12 (80) | - |
| Skin and soft tissue | 2 (22) | 3 (20) | - |
| Surgical site | 0 | 4 (27) | - |
| Species isolated, No. (%) | - | ||
| M. chelonae | 1 (11) | 1 (7) | - |
| M. abscessus complex | 5 (56) | 4 (27) | - |
| M. abscessus abscessus | 2 (22) | 6 (40) | - |
| M. abscessus bolleti | 2 (22) | 2 (13) | - |
| M. abscessus massiliense | 0 | 4 | - |
| Days of therapy, median (IQR) | 24 (19–79) | 48 (25–211) | .31 |
| Baseline platelet count, median (IQR), /µL | 220 (156–253) | 181 (93–304) | .91 |
| Baseline absolute neutrophil count, median (IQR), /µL | 5 (3–8) | 4 (2–5) | .36 |
| Baseline hemoglobin, median (IQR), g/dL | 10 (9–10) | 9 (8–10) | .24 |
| Initial daily linezolid dose, No. (%) | - | ||
| 300 mg | 1 (11) | - | - |
| 600 mg | 3 (33) | - | - |
| 1200 mg | 5 (56) | - | - |
| Initial daily tedizolid dose, No. (%) | - | ||
| 200 mg | - | 14 (93) | - |
| 400 mg | - | 1 (7) | - |
Abbreviations: BMI, body mass index; CHF, chronic heart failure; COPD, chronic obstructive pulmonary disease; CrCl, creatinine clearance; ESRD, end-stage renal disease; IQR, interquartile range.
aDefined by Cockcroft-Gault equation.
bReported NTM isolate from blood culture and another site.